

Track record – Diseases – Other

Discontinuing Inappropriate Medication in Nursing Home Residents (DIM-NHR Study): protocol of a cluster randomised controlled trial. Wouters H, Quik EH, Boersma F, Nygård P, Bosman J, Böttger WM, Mulder H, Maring JG, Wijma-Vos L, Beerden T, van Doormaal J, Postma MJ, Zuidema SU, Taxis K. *BMJ open*. 2014 Oct 8;4(10):e006082. doi: 10.1136/bmjopen-2014-006082.

Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence. van Boven JF, Stuurman-Bieze AG, Hiddink EG, Postma MJ, Vegter S.J *Manag Care Pharm*. 2014 Aug;20(8):786-92.

The effect of financial and educational incentives on rational prescribing. A state-space approach. Pechlivanoglou P, Wieringa JE, de Jager T, Postma MJ. *Health Econ*. 2014 Feb 11. doi: 10.1002/hec.3030. [Epub ahead of print]

Differential time preferences for money and quality of life. Parouty MB, Le HH, Krooshof D, Postma MJ. *Pharmacoeconomics*. 2014 Apr;32(4):411-9. doi: 10.1007/s40273-013-0124-8.

Costs and benefits of individuals conceived after IVF: a net tax evaluation in The Netherlands. Moolenaar LM, Connolly M, Huisman B, Postma MJ, Hompes PG, van der Veen F, Mol BW. *Reprod Biomed Online*. 2014 Feb;28(2):239-45. doi: 10.1016/j.rbmo.2013.10.002. Epub 2013 Oct 10.

Effect of breastfeeding promotion interventions on cost-effectiveness of rotavirus immunization in Indonesia. Suwantika AA, Postma MJ. *BMC Public Health*. 2013 Dec 1;13:1106. doi: 10.1186/1471-2458-13-1106.

Determinants of Increasing the Likelihood for a Positive Drug Reimbursement Recommendation in Scotland. Pantiri K, Baeten S, Majer I, Heeg B, Charokopou M. *HC1 –Value in Health* 11/2014; 17(7):A325.

Comparison of factors influencing reimbursement and coverage decisions in Scotland (SMC), the Netherlands (NZI) and Germany (G-BA) Charokopou M, Alleman CJ, Verleger K, Spoorendonk JA, Schmidt R, Schoeman O, Heeg B *Value in Health* 11/2014; 17(7):A325.

Factors influencing dutch drug reimbursement recommendations; a database analysis. Alleman CJ, Spoorendonk JA, Charokopou M, Hensen M, Heeg B *Value in health* 2014

Validation of the Adherence Barriers Questionnaire (ABQ) – An Instrument for Identifying Potential Risk Factors Associated With Medication-Related Non-Adherence. Müller S, Wilke T. *Value in Health*. 2014;17(7):A512.

Reviewing and piloting methods for decreasing discount rates; someone, somewhere in time. Parouty MB, Krooshof DG, Westra TA, Pechlivanoglou P, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2013 Aug;13(4):523-47. doi: 10.1586/14737167.2013.815404.

The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. Visser ST, Schuiling-Veninga CC, Bos JH, de Jong-van den Berg LT, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2013 Jun;13(3):285-92. doi: 10.1586/erp.13.20.

Accumulating evidence for the case of differential discounting. Postma MJ, Parouty M, Westra TA. *Expert Rev Clin Pharmacol*. 2013 Jan;6(1):1-3. doi: 10.1586/ecp.12.73. No abstract available.

A Model to Evaluate the Immunogenicity Costs of Tumour Necrosis Factor-Alpha Inhibitors in Patients with Rheumatoid Arthritis. Heeg B, Majer I, Stephens J, Tarallo M. *Value in Health*, Vol. 16, Issue 7, A563. November, 2013

Comparison of Coverage and Reimbursement Decisions in Germany (AMNOG) and Scotland (SMC). Charokopou M, Heeg B, Schoeman O, Müller S, Tempest M.J, Schlagmuller S.C, Wilke T. *A Value in Health*. 2013;16(7):A475–A476.

The Impact of AMNOG on Drug Reimbursement in Germany. Heeg B, Schoeman O, Müller S, Wilke T. *Value in Health*. 2013;16(7):A459.

The use and impact of value of information analysis in decision-making. Chuang L H, Treur M, Heeg B, Van Hout B, Filonenko A. *A30. Value in Health* 05/2013; 16(3):

Practical implications of differential discounting of costs and health effects in cost-effectiveness analysis. Westra TA, Parouty MB, Wilschut JC, Boersma C, Postma MJ. *Value Health*. 2011 Dec;14(8):1173-4; author reply 1174-5. doi: 10.1016/j.jval.2011.07.013. Epub 2011 Nov 12. No abstract available.

Factors Influencing Drug Reimbursement Decision in Scotland. Charokopou M., Heeg B., Majer I.M.. *RE1 Value in Health* 11/2012; 15(7):A287.

The long-term fiscal impact of funding cuts to Danish public fertility clinics. Connolly MP, Postma MJ, Crespi S, Andersen AN, Ziebe S. *Reprod Biomed Online*. 2011 Dec;23(7):830-7. doi: 10.1016/j.rbmo.2011.09.011. Epub 2011 Sep 29.

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. Vegter S, Tolley K, Keith MS, Postma MJ. *Value Health*. 2011 Sep-Oct;14(6):852-8. doi: 10.1016/j.jval.2011.05.005. Epub 2011 Jun 23.

Analyzing generic and branded substitution patterns in the Netherlands using prescription data. Pechlivanoglou P, van der Veen WJ, Bos JH, Postma MJ. *BMC Health Serv Res*. 2011 Apr 27;11:89. doi: 10.1186/1472-6963-11-89.

Preventable hospital admissions related to medication (HARM): cost analysis of the HARM study. Leendertse AJ, Van Den Bemt PM, Poolman JB, Stoker LJ, Egberts AC, Postma MJ. *Value Health*. 2011 Jan;14(1):34-40. doi: 10.1016/j.jval.2010.10.024.

Toward Identifying the Causes and Combinations of Causes Increasing the Risks of Nonadherence to Medical Regimens: Combined Results of Two German Self-Report Surveys. Wilke T, Müller S, Morisky D.E. *Value in Health*. 2011;14(8):1092–1100.

Does the package design matter? The influence of OTC package design on patients' drug knowledge. Wilke T, Müller S, Neumann K, Loder T. *Pharmaceutical Medicine*. 2011;25(5):307-317.

Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Westra TA, de Vries R, Tamminga JJ, Sauboin CJ, Postma MJ. *Clin Ther*. 2010 Aug;32(8):1479-95. doi: 10.1016/j.clinthera.2010.07.017.

Non-Adherence in outpatient prophylaxis after major orthopedic surgery. Wilke T, Mook J, Müller S, Obert S, Pfannkuche M, Kurth A. 2010. *Clin Orthop Relat Res*. 2010;468(9):2437–2453.

Comparing forecasted with actual budget impact: reimbursed cancer drugs in the Netherlands. Thuresson B, Heeg B, Botteman M. *PCN32. Value in Health* 01/2010; 13(7).

Does the package design matter? The influence of OTC package design on patients' drug knowledge. Wilke T, Müller S, K. Neumann K, Loder T. *Value and Health*. 2010;13(7):A421.

The impact of medication switches induced by medication discount contracts on chronic patients' adherence. Groth A, Müller S, Wilke T. *Value in Health*. 2010;13(7):A360

Why do patients not adhere to prescribed medication regimes? Results of two German surveys. Wilke T, Müller S. *Value in Health*. 2010;13(7):A380.

Economics of assisted reproduction: access to fertility treatments and valuing live births in economic terms. Connolly MP, Ledger W, Postma MJ. *Hum Fertil (Camb)*. 2010 Mar;13(1):13-8. doi: 10.3109/14647270903401747. Review.

Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands. van Hulst M, Hubben GA, Sagoe KW, Promwong C, Permpikul P, Fongsatitkul L, Glynn DM, Sibinga CT, Postma MJ. *Transfusion*. 2009 Dec;49(12):2729-42. doi: 10.1111/j.1537-2995.2009.02351.x. Epub 2009 Aug 25.

The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: a price-elasticity of demand assessment. Connolly MP, Griesinger G, Ledger W, Postma MJ. *Hum Reprod*. 2009 Nov;24(11):2796-800. doi: 10.1093/humrep/dep260. Epub 2009 Jul 22.

The dynamic field of pharmacoeconomics. Postma MJ. *Expert Rev Clin Pharmacol*. 2009 Mar;2(2):125-7. doi: 10.1586/17512433.2.2.125.

Cost-effectiveness of a potential future *Helicobacter pylori* vaccine in the Netherlands: the impact of varying the discount rate for health. de Vries R, Klok RM, Brouwers JR, Postma MJ. *Vaccine*. 2009 Feb 5;27(6):846-52. doi: 10.1016/j.vaccine.2008.11.081. Epub 2008 Dec 11.

Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ. *Pharmacoeconomics*. 2008;26(7):569-87. Review.

Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression. Treur M, McCracken F, Heeg B, Joshi AV, Botteman M, De Charro F, van Hout B. *Haemophilia* 04/2009; 15(2):420-36.

Economic evaluation of folic acid food fortification in The Netherlands. Jentink J, van de Vrie-Hoekstra NW, de Jong-van den Berg LT, Postma MJ. *Eur J Public Health*. 2008 Jun;18(3):270-4. doi: 10.1093/eurpub/ckm129. Epub 2008 Jan 31.

Enhanced decision support for policy makers using a web interface to health-economic models—illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Hubben GA, Bos JM, Glynn DM, van der Ende A, van Alphen L, Postma MJ. *Vaccine*. 2007 May 4;25(18):3669-78. Epub 2007 Feb 5.

Adherence of pharmacoeconomic studies to national guidelines in the Netherlands. Atthobari J, Bos JM, Boersma C, Brouwers JR, de Jong-van den Berg LT, Postma MJ. *Pharm World Sci*. 2005 Oct;27(5):364-70.

Discounting health effects in pharmacoeconomic evaluations: current controversies. Bos JM, Postma MJ, Annemans L. *Pharmacoeconomics*. 2005;23(7):639-49.

The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Welte R, Trotter CL, Edmunds WJ, Postma MJ, Beutels P. *Pharmacoeconomics*. 2005;23(9):855-74. Review.

Need for differential discounting of costs and health effects in cost effectiveness analyses. Brouwer WB, Niessen LW, Postma MJ, Rutten FF. *BMJ*. 2005 Aug 20;331(7514):446-8. No abstract available.

Towards a healthier discount procedure. Klock RM, Brouwer WB, Annemans LJ, Bos JM, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2005 Feb;5(1):59-63. doi: 10.1586/14737167.5.1.59.

Four quadrants of the cost-effectiveness plane: some considerations on the south-west quadrant. Klok RM, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2004 Dec;4(6):599-601. doi: 10.1586/14737167.4.6.599. No abstract available.

Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness? Bos JM, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2004 Jun;4(3):247-50. doi: 10.1586/14737167.4.3.247. No abstract available.

Impact of pharmacist recommendations on the cost of drug therapy in ICU patients at a Malaysian hospital. Zaidi ST, Hassan Y, Postma MJ, Ng SH. *Pharm World Sci*. 2003 Dec;25(6):299-302.

Pharmacoeconomic research. Postma MJ. *Pharm World Sci*. 2003 Dec;25(6):245-6.

[Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations]. Postma MJ, Kwik JJ, Rutten WJ, de Jong-van den Berg LT, Brouwers JR. *Ned Tijdschr Geneesk*. 2002 Jun 8;146(23):1082-7. Dutch.

Cost-effectiveness of periconceptual supplementation of folic acid. Postma MJ, Londeman J, Veenstra M, de Walle HE, de Jong-van den Berg LT. *Pharm World Sci*. 2002 Feb;24(1):8-11.

Cost-benefit analysis of the detection of prescribing errors by hospital pharmacy staff. van den Bemt PM, Postma MJ, van Roon EN, Chow MC, Fijn R, Brouwers JR. *Drug Saf*. 2002;25(2):135-43.

Projecting utilization of hospital in-patient days in The Netherlands: a time-series analysis. Postma MJ, Ruwaard D, Jager HJ. *IMA J Math Appl Med Biol*. 1995 Sep-Dec;12(3-4):185-202.